cholesterol

What providers need to do to improve chronic careA West survey finds that an overwhelming number of chronic care patients say they need help managing their disease.
Value-based care takes over J.P. Morgan Healthcare Conference 2017Is the drive to value-based care really accelerating? What can be done amidst all of the uncertainty? Expert shares insights from the J.P. Morgan 35th Annual Healthcare Conference.
Study: Statin users less likely to develop kidney stonesA large new study provides more evidence that cholesterol drugs may lower kidney stone formation.
How providers, payers, employers should be fighting obesityBy addressing the root problem of obesity with structured programs, providers can help patients lose weight and very possibly avoid expensive chronic illnesses as a result. Employers and payers should incentivize healthy weight by paying for obesity care and treatment, potentially reaping substantial savings in the long term.
How your pharmacy partners impact your Star RatingsAre you tracking your prospective pharmacy partners to measure their potential impact on your Star Rating? You should be.
FDA no longer supports use of niacin, fenofibric acid with statinsFDA has withdrawn its approval for niacin and fenofibric acid use with statins to treat high cholesterol.
Watch list 2016: Top therapeutic areas
Watch list 2016: Top therapeutic areasExperts say you should follow these 6 therapeutic areas.
Study models way to optimize cholesterol drug valueStudy provides five key takeaways for managed care executives. View the five takeaways.
How Express Scripts will manage pricey cholesterol drugsAfter much criticism on the price of 2 new cholesterol-lowering drugs, Praluent and Repatha, Express Scripts said this week it will now include both drugs in its National Preferred Formulary.
High cost of new PCSK9 inhibitors could plague payersThe high cost of these medications could overwhelm patients and plans, according to one expert.